Amarin | AMRN - Ordinary Share Capital


Amarin reported $20.8M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amarin USD 20.8M 28K Sep/2025
AstraZeneca USD 1.55B 206K Dec/2025
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
DBV Technologies USD 11.65M 1000 Mar/2025
Esperion Therapeutics USD 112K 11K Sep/2023
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Halozyme Therapeutics USD 117.78M 259K Dec/2025
Heron Therapeutics USD 1.52M 14K Sep/2024
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Nektar Therapeutics USD 19K 0 Sep/2024
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.94B 23.4M Jun/2025